REGN7508 is a monoclonal antibody designed to target Factor XI. It is being studied for its potential to prevent venous thromboembolism, which is a condition where blood clots form in the veins, in patients who are undergoing elective, unilateral total knee replacement surgery. The goal is to see if this medication can effectively reduce the risk of blood clots compared to other treatments.

Enoxaparin is a medication commonly used to prevent and treat blood clots. It is often given to patients undergoing surgery to reduce the risk of developing venous thromboembolism. In this study, enoxaparin is used as a comparison to evaluate the effectiveness of REGN7508 in preventing blood clots after knee surgery.

Thromboembolic disease – This condition involves the formation of blood clots that can obstruct blood vessels. It often occurs in veins, leading to venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT typically develops in the deep veins of the legs, causing pain and swelling. If a part of the clot breaks off, it can travel to the lungs, resulting in a PE, which can cause chest pain and difficulty breathing. The disease progresses as clots form and potentially dislodge, leading to complications. It is often associated with periods of immobility, surgery, or certain medical conditions that increase clotting risk.